xembify normal immunoglobulin 2 g/10 ml (20%) solution for subcutaneous injection vial
grifols australia pty ltd - human immunoglobulin g, quantity: 1800 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.
hipraject subcutaneous
hipra philippines, inc.; distributor: hipra philippines, inc. - subcutaneous vaccination device (vet.) - subcutaneous - not applicable
neo-mercazole
aft pharmaceuticals ltd - carbimazole 5mg; ; carbimazole 5mg - tablet - 5 mg - active: carbimazole 5mg excipient: acacia gelatin iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propyl hydroxybenzoate purified talc sucrose active: carbimazole 5mg excipient: acacia gelatin iron oxide red lactose monohydrate magnesium stearate maize starch purified talc sucrose - primary thyrotoxicosis, even in pregnancy. secondary thyrotoxicosis - toxic nodular goitre. however, neo-mercazole really has three principal applications in the therapy of hyperthyroidism: 1. definitive therapy - induction of a permanent remission. 2. preparation for thyroidectomy. 3. before and after radio-active iodine treatment.
utibron neohaler- indacaterol and glycopyrrolate capsule
novartis pharmaceuticals corporation - indacaterol maleate (unii: 2jec1itx7r) (indacaterol - unii:8or09251mq), glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - indacaterol 27.5 ug - utibrontm neohaler® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use: utibron neohaler is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see warnings and precautions (5.1, 5.2)] . all labas are contraindicated in patients with asthma without use of a long-term asthma control medication [see warnings and precautions (5.1)] . utibron neohaler is not indicated for the treatment of asthma. utibron neohaler is contraindicated in patients who have demonstrated hypersensitivity to indacaterol, glycopyrrolate, or to any of the ingredients [see warnings and precautions (5.5)] . teratogenic effects: pregnancy category c there are no adequate and well-controlled studies with utibron neohaler or its individual components, indacaterol and glycopyrrolate, in pregnant women
tavneos
cts ltd - avacopan - hard capsule - avacopan 10 mg - avacopan - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
transiderm-nitro 25 glyceryl trinitrate 25 mg transdermal drug delivery system sachet
sandoz pty ltd - glyceryl trinitrate, quantity: 25 mg - drug delivery system, transdermal - excipient ingredients: lactose monohydrate; dimeticone; colloidal anhydrous silica; polyethylene terephthalate; aluminium; ethylene/vinyl acetate copolymer; polyvinyl chloride; trichlorotrifluoroethane; simethicone - indicated for the prevention of chronic stable angina pectoris due to coronary artery disease.
betnovate scalp application 0.1% w/v cutaneous solution
glaxosmithkline (ireland) limited - betamethasone - cutaneous solution - 0.1 percent weight/volume - corticosteroids, potent (group iii); betamethasone
bettamousse 1mg/g (0.1%) cutaneous foam
rph pharmaceuticals ab - betamethasone valerate - cutaneous foam - 1 (0.1%) milligram(s)/gram - corticosteroids, potent (group iii); betamethasone
dermovate scalp application 0.05% w/v cutaneous solution
glaxosmithkline (ireland) limited - clobetasol propionate - cutaneous solution - 0.05 percent weight/volume - corticosteroids, very potent (group iv); clobetasol
difene spray gel 4 %w/w cutaneous spray solution
astellas pharma co. ltd - diclofenac sodium - cutaneous spray solution - 4 %w/w - antiinflammatory preparations, non-steroids for topical use